Panoptic Bio offers clinical trial intelligence that integrates biological, regulatory, and business data to predict trial outcomes more accurately. Their industry‑leading trial prediction platform helps pharmaceutical companies identify high‑value trials and reduce failure rates, aiming to accelerate the development of new treatments. By providing quantitative outcome forecasts, Panoptic Bio enables more efficient R&D investment and improves the likelihood of successful market entry.
Funding
Funding not disclosed
Founders
Product
Problem
Pharmaceutical companies lack quantitative predictions for clinical trial outcomes and have fragmented biological, regulatory, and business data, leading to inconsistent trial valuations and a high failure rate that slows drug development.
Solution
Panoptic Bio offers a platform that integrates biological, regulatory, and commercial datasets to generate quantitative predictions of clinical trial success. Its proprietary trial prediction engine produces probabilistic outcome forecasts and a standardized valuation of trial prospects. By delivering these insights in a single interface, the platform enables R&D teams to prioritize assets, allocate resources more efficiently, and reduce the risk of costly trial failures. The resulting data‑driven decisions aim to increase the proportion of trials that reach market approval, accelerating the delivery of new therapies to patients.
Target Audience
Primary customers are pharmaceutical R&D organizations and biotech firms that manage large clinical trial portfolios and need data‑driven tools to assess trial risk and value.
Features
- Unified data lake combining genomic, preclinical, regulatory, and market information for each trial candidate
- Machine‑learning prediction engine that outputs probability of success and expected financial return for individual trial phases
- Consistent valuation framework that translates predictive metrics into comparable monetary estimates
- Interactive dashboard for scenario analysis, portfolio optimization, and risk assessment
- API access for integration with internal drug development pipelines and decision‑support tools